Pfizer, the pharmaceutical giant that has become a cash-generating machine thanks to its coronavirus vaccine, is bringing Global Blood Therapeutics into a $5.4 billion all-cash deal announced on Monday.
The acquisition of the company behind one of the few FDA-approved treatments for sickle cell disease is the latest blockbuster deal for Pfizer, which has been seeking veins of long-term growth following a financial windfall driven by its COVID-19 vaccine.
In May, it spent $11.6 billion to swallow Biohaven Pharmaceutical Holding, which deals acute migraines.
Most recently, he shelled out $6.7 billion for Arena Pharmaceuticalswhich focuses on immuno-inflammatory diseases such as Crohn’s disease.
Pfizer Chief Executive Albert Bourla said the deal was to dedicate resources to new treatments for an underserved patient community.
UPS acquires Bomi Group
UPS announced plans to acquire Italian healthcare logistics company Bomi Group to expand the reach of its healthcare unit globally.
With this acquisition, UPS said it would gain temperature-controlled facilities in 14 countries, 350 temperature-controlled vehicles and nearly 3,000 employees in Europe and Latin America.
Kate Gutmann, president of UPS International, healthcare and supply chain, said the agreement with Bomi accelerates UPS’s journey “to become the premier provider of complex healthcare logistics.”
The companies did not disclose the value of the transaction. UPS is acquiring Bomi from healthcare investment firm ArchiMed, which said it bought Bomi in 2019 for 100 million euros.
Since then, Bomi has made a series of acquisitions and increased its turnover.
From thread reports